MyFinsight
Home
Blog
About
Back
Income Statement
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)
source: myfinsight.com
Net gain
-$20,173,129
(-657.76%↓ Y/Y)
Total other income
(expense)
-$13,894,369
(-812161.31%↓ Y/Y)
Loss from operations
-$6,278,760
(-135.70%↓ Y/Y)
Realized gain on sale of
digital assets
$1,704,378
Trading gains, net
$282,989
Digital assets received
as yield income
$282,732
Change in fair value of
derivative
-$215,993
Interest income
$21,764
(42.74%↑ Y/Y)
Foreign currency
gains/(losses), net
$458
Unrealized gain from
changes in fair value of...
-$13,178,928
Interest expense
$3,223,755
(13883.50%↑ Y/Y)
Total operating
expenses
$6,278,760
(135.70%↑ Y/Y)
General and
administrative expenses
$5,319,018
(164.35%↑ Y/Y)
Research and development
expenses
$959,742
(47.25%↑ Y/Y)
Back